Status: Not yet recruiting
2-Hydroxybenzylamine (2-HOBA) Study in Early Alzheimer's Patients
Investigators propose a phase 1b/2a, randomized, double-blind, placebo-controlled, parallel group dose finding and biomarker study to evaluate the safety, tolerability, and biomarker activity of 2-HOBA in 48 MCI/AD participants. Participants will be randomized 1:1:1:1 to receive 250 mg BID, 250 and 500 mg 2-HOBA acetate TID or placebo for 12 weeks. Blood and cerebral spinal fluid (CSF) will be collected to measure markers of protein modification by dicarbonyls (IsoLGs- \& MDA), pTau-181, YKL-40, and NF-L.
Participants needed: 48
Trial details
Phase: Phase 1, Phase 2Age: 55-85Biological sex: AllType: InterventionalSponsor: MTI Biotech IncUpdated: Sep 24, 2026Locations: 1
Eligibility criteria
Male or female, aged 55-85 years (both inclusive) at the time of signing informe... [+22]
Use centrally acting anti-cholinergic drugs. [+1]